Lucentis (Ranibizumab Injection) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

February 9, 2012

Lucentis

Macular Degeneration »

Macular degeneration facts

The macula is in the center of the retina, the light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision (straight-ahead vision). Degeneration of the macula occurs most often after the age of 60 years and is termed age-related macular generation (AMD).
AMD is a painless condition.
There are two types of AMD: dry AMD and wet AMD.
Smoking, high blood pressure, obesity, a diet high in unsaturated fats and simple carbohydrates and lack of exercise all increase the risk of AMD.
Early symptoms of dry AMD include slightly blurred vision, the need for more light for reading, and difficulty recognizing faces until very close to the person. A symptom of more advanced dry AMD is the presence of a blurred spot in the center of vision. An early symptom of wet AMD is the wavy appearance of straight lines.
Dry AMD cannot be treated...

Read the Macular Degeneration article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
next »

Lucentis User Reviews >>

Lucentis

Eye Diseases and Conditions Slideshow Pictures

Pink Eye Slideshow Pictures

Cataracts Slideshow Pictures

font size

LUCENTIS
(ranibizumab injection) Intravitreal Injection

DRUG DESCRIPTION

LUCENTIS® (ranibizumab injection) is a recombinant humanized IgGl kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

LUCENTIS (ranibizumab injection) is a sterile, colorless to pale yellow solution in a single-use glass vial. LUCENTIS (ranibizumab injection) is supplied as a preservative-free, sterile solution in a single-use glass vial designed to deliver 0.05 mL of 10 mg/mL LUCENTIS (ranibizumab injection) aqueous solution with 10 mM histidine HC1, 10% a,a-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.

What are the possible side effects of ranibizumab (Lucentis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

vision changes;
eye pain, redness, or irritation;
discharge or bleeding from the eye;
increased eye sensitivity to light;
swelling around your eye;
seeing "stars" or flashes of light, especially in your peripheral (side) vision;

Read All Potential Side Effects and See Pictures of Lucentis »

What are the precautions when taking ranibizumab injection (Lucentis)?

Before receiving ranibizumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have a certain medical condition. Before using this medicine, consult your doctor or pharmacist if you have: a current eye infection.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is not known whether this drug passes into breast milk. However, this medication is unlikely to pass into breast milk. Consult your doctor before...

Read All Potential Precautions of Lucentis »

Last reviewed on RxList: 7/21/2010
This monograph has been modified to include the generic and brand name in many instances.